Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. (Q34566470)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

19 January 2020

main subject

placebo

0 references

0 references

Crohn's disease

0 references

placebo-controlled trial

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Mario Cottone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

C Prantera

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

H Lochs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M L Scribano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

G C Sturniolo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

F Castiglione

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

1117-1125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16611272%20AND%20SRC:MED&resulttype=core&format=json

Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Preliminary study of ciprofloxacin in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Rifaximin: a review of its use in the management of traveller's diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Management of diverticular disease: is there room for rifaximin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

Antibiotic use and the risk of flare of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X

C-reactive protein as a marker for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02879.X